242 related articles for article (PubMed ID: 31632294)
1. Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage: Different Dynamics of Changes.
Fiedorowicz M; Choragiewicz T; Thaler S; Schuettauf F; Nowakowska D; Wojtunik K; Reibaldi M; Avitabile T; Kocki T; Turski WA; Kaminska A; Grieb P; Zrenner E; Rejdak R; Toro MD
Front Physiol; 2019; 10():1254. PubMed ID: 31632294
[TBL] [Abstract][Full Text] [Related]
2. Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients.
Oxenkrug G; van der Hart M; Roeser J; Summergrad P
Integr Clin Med; 2017; 1(1):. PubMed ID: 28748226
[TBL] [Abstract][Full Text] [Related]
3. Effect of Kynurenic Acid on Pupae Viability of Drosophila melanogaster cinnabar and cardinal Eye Color Mutants with Altered Tryptophan-Kynurenine Metabolism.
Navrotskaya V; Wnorowski A; Turski W; Oxenkrug G
Neurotox Res; 2018 Aug; 34(2):324-331. PubMed ID: 29619629
[TBL] [Abstract][Full Text] [Related]
4. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
[TBL] [Abstract][Full Text] [Related]
5. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
6. Kynurenic acid and 3-hydroxykynurenine production from D-kynurenine in mice.
Wang XD; Notarangelo FM; Wang JZ; Schwarcz R
Brain Res; 2012 May; 1455():1-9. PubMed ID: 22498176
[TBL] [Abstract][Full Text] [Related]
7. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
8. Kynurenine pathway changes in late-life depression.
Wu Y; Zhong X; Mai N; Wen Y; Shang D; Hu L; Chen B; Zhang M; Ning Y
J Affect Disord; 2018 Aug; 235():76-81. PubMed ID: 29655078
[TBL] [Abstract][Full Text] [Related]
9. The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway.
Guloksuz S; Arts B; Walter S; Drukker M; Rodriguez L; Myint AM; Schwarz MJ; Ponds R; van Os J; Kenis G; Rutten BP
Brain Behav Immun; 2015 Aug; 48():48-52. PubMed ID: 25765557
[TBL] [Abstract][Full Text] [Related]
10. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
[TBL] [Abstract][Full Text] [Related]
11. Role of d-amino acid oxidase in the production of kynurenine pathway metabolites from d-tryptophan in mice.
Notarangelo FM; Wang XD; Horning KJ; Schwarcz R
J Neurochem; 2016 Feb; 136(4):804-814. PubMed ID: 26661897
[TBL] [Abstract][Full Text] [Related]
12. Unlocking the potential of the 3-hydroxykynurenine/kynurenic acid ratio: a promising biomarker in adolescent major depressive disorder.
Ye Z; Yang S; Lu L; Zong M; Fan L; Kang C
Eur Arch Psychiatry Clin Neurosci; 2024 May; ():. PubMed ID: 38819463
[TBL] [Abstract][Full Text] [Related]
13. Kynurenine and its metabolites in Alzheimer's disease patients.
Gulaj E; Pawlak K; Bien B; Pawlak D
Adv Med Sci; 2010; 55(2):204-11. PubMed ID: 20639188
[TBL] [Abstract][Full Text] [Related]
14. Kynurenine pathway changes in late-life depression with memory deficit.
Wu Y; Mai N; Zhong X; Wen Y; Zhou Y; Li H; Shang D; Hu L; Chen X; Chen B; Zhang M; Ning Y
Psychiatry Res; 2018 Nov; 269():45-49. PubMed ID: 30145300
[TBL] [Abstract][Full Text] [Related]
15. Different Kynurenine Pathway Dysregulation in Systemic Sclerosis in Men and Women.
Turska-Kozłowska M; Pedraz-Petrozzi B; Paluszkiewicz P; Parada-Turska J
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612652
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.
Oxenkrug G; van der Hart M; Roeser J; Summergrad P
Endocrinol Diabetes Metab J; 2017 Nov; 1(4):. PubMed ID: 29292800
[TBL] [Abstract][Full Text] [Related]
17. Changes in the plasma concentrations of D-kynurenine and kynurenic acid in rats after intraperitoneal administration of tryptophan enantiomers.
Ishii K; Ogaya T; Song Z; Iizuka H; Fukushima T
Chirality; 2010 Nov; 22(10):901-6. PubMed ID: 20872665
[TBL] [Abstract][Full Text] [Related]
18. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
[TBL] [Abstract][Full Text] [Related]
19. Perinatal kynurenine pathway metabolism in the normal and asphyctic rat brain.
Ceresoli-Borroni G; Schwarcz R
Amino Acids; 2000; 19(1):311-23. PubMed ID: 11026502
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.
Aeinehband S; Brenner P; Ståhl S; Bhat M; Fidock MD; Khademi M; Olsson T; Engberg G; Jokinen J; Erhardt S; Piehl F
Brain Behav Immun; 2016 Jan; 51():47-55. PubMed ID: 26189678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
